Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : HuMAB companies -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (50)	9/11/2000 12:03:34 PM
From: nigel bates	Read Replies (1) \| Respond to of 1022

From the Genmab announcement - "Genmab has corporate collaborations with Medarex, Inc., a leading US antibody company, and Immunex Corporation. It also has access to novel genomics targets from both Eos Biotechnology, Inc. and Oxford GlycoSciences (LSE: OGS.L - news) Plc. Through its unique alliance with Medarex, Genmab has broad access to Medarex's patented HuMAb-Mouse(R) technology, as well as to the TC Mouse(TM) technology developed by Kirin Brewery Co.Ltd. Genmab's relationship with Medarex was recently expanded, providing it with rights to market these technologies for genomics alliances in Europe and the potential to collaborate with Medarex and target companies to develop antibody products to genomics and other novel targets. Genmab was founded as an independent company in Copenhagen in February 1999, through the joint efforts of Medarex and a group of Danish investors, to develop and commercialise a portfolio of fully human antibodies." ...Sounds a bit like a semi-independent European offshoot of MEDX...even down to the collaboration with OGS. nig